Preclinical in vitro and in vivo characterization of the fully human monoclonal IgM antibody KBPA101 specific for Pseudomonas aeruginosa serotype IATS-O11

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 6, 2010, Pages 2338-2344

  Horn, Michael P ^a,c   Zuercher, Adrian W ^a,d   Imboden, Martin A ^a,d   Rudolf, Michael P ^a   Lazar, Hedvika ^a   Wu, Hong ^b   Hoiby, Niels ^b   Fas, Stefanie C ^a   Lang, Alois B ^a,e  

^a Kenta Biotech AG   (Switzerland)

^b University of Copenhagen   (Denmark)

^c UNIVERSITY OF BERN   (Switzerland)

^d CSL Behring   (Switzerland)

^e GENEURO SA   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN M; KBPA101; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BURN; CELL STRAIN HL 60; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HUMAN; HUMAN TISSUE; HYBRIDOMA CELL CULTURE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OPSONIZATION; PHAGOCYTOSIS; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; RESPIRATORY TRACT INFECTION; SEROTYPE; VENTILATOR ASSOCIATED PNEUMONIA; WOUND INFECTION;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODIES, MONOCLONAL; ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; BASE SEQUENCE; CELL LINE; COMPLEMENT SYSTEM PROTEINS; DISEASE MODELS, ANIMAL; DNA PRIMERS; HL-60 CELLS; HUMANS; HYBRIDOMAS; IMMUNOGLOBULIN M; MICE; PHAGOCYTOSIS; PNEUMONIA, BACTERIAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RABBITS; SEPSIS; SEROTYPING;

EID: 77952616726     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01142-09     Document Type: Article

References (48)

1. Bruderer, U., S. J. Cryz, Jr., U. B. Schaad, M. Deusinger, J. U. Que, and A. B. Lang. 1992. Affinity constants of naturally acquired and vaccine-induced anti-Pseudomonas aeruginosa antibodies in healthy adults and cystic fibrosis patients. J. Infect. Dis. 166:344-349.
2. Casadevall, A., E. Dadachova, and L. A. Pirofski. 2004. Passive antibody therapy for infectious diseases. Nat. Rev. Microbiol. 2:695-703.
3. Crouch Brewer, S., R. G. Wunderink, C. B. Jones, and K. V. Leeper, Jr. 1996. Ventilator-associated pneumonia due to Pseudomonas aeruginosa. Chest 109:1019-1029.
4. Cryz, S. J., Jr., E. Furer, and R. Germanier. 1983. Protection against Pseudomonas aeruginosa infection in a murine burn wound sepsis model by passive transfer of antitoxin A, antielastase, and antilipopolysaccharide. Infect. Immun. 39:1072-1079.
5. Cryz, S. J., Jr., A. Lang, A. Rudeberg, J. Wedgwood, J. U. Que, E. Furer, and U. Schaad. 1997. Immunization of cystic fibrosis patients with a Pseudomonas aeruginosa O-polysaccharide-toxin A conjugate vaccine. Behring Inst. Mitt:345-349.
6. Cryz, S. J., Jr., A. B. Lang, J. C. Sadoff, R. Germanier, and E. Furer. 1987. Vaccine potential of Pseudomonas aeruginosa O-polysaccharide-toxin A conjugates. Infect. Immun. 55:1547-1551.
7. Desgranges, C., M. F. Lavoue, J. Patet, and G. de-The. 1979. In vitro transforming activity of Epstein-Barr virus (EBV). II. Differences between M81 and B95-8 EBV strains. Biomedicine 30:102-108.
8. Doring, G., and G. B. Pier. 2008. Vaccines and immunotherapy against Pseudomonas aeruginosa. Vaccine 26:1011-1024.
9. Eggimann, P., S. Hugonnet, H. Sax, S. Touveneau, J. C. Chevrolet, and D. Pittet. 2003. Ventilator-associated pneumonia: caveats for benchmarking. Intensive Care Med. 29:2086-2089.
10. Eggimann, P., and D. Pittet. 2001. Infection control in the ICU. Chest 120:2059-2093.
11. Falk, G. A., A. J. Okinaka, and G. W. Siskind. 1972. Immunoglobulins in the bronchial washings of patients with chronic obstructive pulmonary disease. Am. Rev. Respir. Dis. 105:14-21.
12. Harrison, F. J., D. Rohm, T. Kohzuki, and H. Noguchi. 1997. Pharmacokinetics, tolerability, and preliminary efficacy of human anti-Pseudomonas aeruginosa monoclonal antibodies in pneumonia and burn infection patients. Hybridoma 16:413-420.
13. Jansen, W. T., J. Gootjes, M. Zelle, D. V. Madore, J. Verhoef, H. Snippe, and A. F. Verheul. 1998. Use of highly encapsulated Streptococcus pneumoniae strains in a flow-cytometric assay for assessment of the phagocytic capacity of serotype-specific antibodies. Clin. Diagn. Lab. Immunol. 5:703-710.
14. Kahzuki, T., I. Uezumi, K. Irie, and H. Ochi. 1991. Human monoclonal antibody and pharmaceutical composition containing the same for treatment of pseudomonas aeruginosa.
15. Knirel, Y. A. 1990. Polysaccharide antigens of Pseudomonas aeruginosa. Crit. Rev. Microbiol. 17:273-304.
16. Kollef, M. H., P. Silver, D. M. Murphy, and E. Trovillion. 1995. The effect of late-onset ventilator-associated pneumonia in determining patient mortality. Chest 108:1655-1662.
17. Kozbor, D., P. Tripputi, J. C. Roder, and C. M. Croce. 1984. A human hybrid myeloma for production of human monoclonal antibodies. J. Immunol. 133: 3001-3005. (Pubitemid 15216494)
18. Landsperger, W. J., K. D. Kelly-Wintenberg, T. C. Montie, L. S. Knight, M. B. Hansen, C. C. Huntenburg, and M. J. Schneidkraut. 1994. Inhibition of bacterial motility with human antiflagellar monoclonal antibodies attenuates Pseudomonas aeruginosa-induced pneumonia in the immunocompetent rat. Infect. Immun. 62:4825-4830.
19. Lang, A. B., E. Furer, G. Senyk, J. W. Larrick, and S. J. Cryz, Jr. 1990. Systematic generation of antigen specific human monoclonal antibodies with therapeutical activities using active immunization. Hum. Antibodies Hybridomas 1:96-103.
20. Lang, A. B., A. Rudeberg, M. H. Schoni, J. U. Que, E. Furer, and U. B. Schaad. 2004. Vaccination of cystic fibrosis patients against Pseudomonas aeruginosa reduces the proportion of patients infected and delays time to infection. Pediatr. Infect. Dis. J. 23:504-510.
21. Lang, A. B., U. B. Schaad, A. Rudeberg, J. Wedgwood, J. U. Que, E. Furer, and S. J. Cryz, Jr. 1995. Effect of high-affinity anti-Pseudomonas aeruginosa lipopolysaccharide antibodies induced by immunization on the rate of Pseudomonas aeruginosa infection in patients with cystic fibrosis. J. Pediatr. 127:711-717.
22. Lang, A. B., U. Schurch, F. Zimmermann, and U. Bruderer. 1992. Selective generation of antigen-specific human hybridomas optimized for large scale growth in serum-free medium. J. Immunol. Methods 154:21-26.
23. Lazar, H., M. P. Horn, A. W. Zuercher, M. A. Imboden, P. Durrer, M. Seiberling, R. Pokorny, C. Hammer, and A. B. Lang. 2009. Pharmacokinetics and safety profile of the human anti-Pseudomonas aeruginosa serotype O11 immunoglobulin M monoclonal antibody KBPA-101 in healthy volunteers. Antimicrob. Agents Chemother. 53:3442-3446.
24. Martinez, J. E., S. Romero-Steiner, T. Pilishvili, S. Barnard, J. Schinsky, D. Goldblatt, and G. M. Carlone. 1999. A flow cytometric opsonophagocytic assay for measurement of functional antibodies elicited after vaccination with the 23-valent pneumococcal polysaccharide vaccine. Clin. Diagn. Lab. Immunol. 6:581-586.
25. Matsumoto, T., K. Tateda, S. Miyazaki, N. Furuya, A. Ohno, Y. Ishii, Y. Hirakata, and K. Yamaguchi. 1999. Effect of antiflagellar human monoclonal antibody on gut-derived Pseudomonas aeruginosa sepsis in mice. Clin. Diagn. Lab. Immunol. 6:537-541.
26. McCloskey, R. V., R. C. Straube, C. Sanders, S. M. Smith, C. R. Smith, et al. 1994. Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 121:1-5.
27. Meng, Y. G., T. Wong, L. D. Saravolatz, and J. E. Pennington. 1993. Pharmacokinetics of an IgM human monoclonal antibody against Pseudomonas aeruginosa in nonseptic patients. J. Infect. Dis. 167:784-785.
28. Muller-Premru, M., and M. Gubina. 2000. Serotype, antimicrobial susceptibility and clone distribution of Pseudomonas aeruginosa in a university hospital. Zentralbl. Bakteriol. 289:857-867.
29. Nagy, E., C. Giefing, and A. von Gabain. 2008. Anti-infective antibodies: a novel tool to prevent and treat nosocomial diseases. Expert Rev. Anti-Infect. Ther. 6:21-30.
30. Ochi, H., H. Ohtsuka, S. Yokota, I. Uezumi, M. Terashima, K. Irie, and H. Noguchi. 1991. Inhibitory activity on bacterial motility and in vivo protective activity of human monoclonal antibodies against flagella of Pseudomonas aeruginosa. Infect. Immun. 59:550-554.
31. Pier, G. B. 2007. Pseudomonas aeruginosa lipopolysaccharide: a major virulence factor, initiator of inflammation, and target for effective immunity. Int. J. Med. Microbiol. 297:277-295.
32. Raymond, C. K., E. H. Sims, A. Kas, D. H. Spencer, T. V. Kutyavin, R. G. Ivey, Y. Zhou, R. Kaul, J. B. Clendenning, and M. V. Olson. 2002. Genetic variation at the O-antigen biosynthetic locus in Pseudomonas aeruginosa. J. Bacteriol. 184:3614-3622.
33. Reichert, J. M., and M. C. Dewitz. 2006. Anti-infective monoclonal antibodies: perils and promise of development. Nat. Rev. Drug Discov. 5:191-195.
34. Reynolds, H. Y., and H. H. Newball. 1974. Analysis of proteins and respiratory cells obtained from human lungs by bronchial lavage. J. Lab. Clin. Med. 84:559-573.
35. Reynolds, H. Y., and R. E. Thompson. 1973. Pulmonary host defenses. I. Analysis of protein and lipids in bronchial secretions and antibody responses after vaccination with pseudomonas aeruginosa. J. Immunol. 111:358-368.
36. Rocchetta, H. L., L. L. Burrows, and J. S. Lam. 1999. Genetics of O-antigen biosynthesis in Pseudomonas aeruginosa. Microbiol. Mol. Biol. Rev. 63:523-553.
37. Rosenthal, V. D., D. G. Maki, A. Mehta, C. Alvarez-Moreno, H. Leblebicioglu, F. Higuera, L. E. Cuellar, N. Madani, Z. Mitrev, L. Duenas, J. A. Navoa-Ng, H. G. Garcell, L. Raka, R. F. Hidalgo, E. A. Medeiros, S. S. Kanj, S. Abubakar, P. Nercelles, and R. D. Pratesi. 2008. International Nosocomial Infection Control Consortium report, data summary for 2002-2007, issued January 2008. Am. J. Infect. Control 36:627-637.
38. Saravolatz, L. D., N. Markowitz, M. S. Collins, D. Bogdanoff, and J. E. Pennington. 1991. Safety, pharmacokinetics, and functional activity of human anti-Pseudomonas aeruginosa monoclonal antibodies in septic and nonseptic patients. J. Infect. Dis. 164:803-806.
39. Sawada, S., T. Kawamura, and Y. Masuho. 1987. Immunoprotective human monoclonal antibodies against five major serotypes of Pseudomonas aeruginosa. J. Gen. Microbiol. 133:3581-3590.
40. Schaad, U. B., A. B. Lang, J. Wedgwood, A. Ruedeberg, J. U. Que, E. Furer, and S. J. Cryz, Jr. 1991. Safety and immunogenicity of Pseudomonas aeruginosa conjugate A vaccine in cystic fibrosis. Lancet 338:1236-1237.
41. Seifert, M., G. Schoenherr, D. Roggenbuck, U. Marx, and R. von Baehr. 1996. Generation and characterization of a human monoclonal IgM antibody that recognizes a conserved epitope shared by lipopolysaccharides of different gram-negative bacteria. Hybridoma 15:191-198. (Pubitemid 26240435)
42. Sekiguchi, J., T. Asagi, T. Miyoshi-Akiyama, A. Kasai, Y. Mizuguchi, M. Araake, T. Fujino, H. Kikuchi, S. Sasaki, H. Watari, T. Kojima, H. Miki, K. Kanemitsu, H. Kunishima, Y. Kikuchi, M. Kaku, H. Yoshikura, T. Kuratsuji, and T. Kirikae. 2007. Outbreaks of multidrug-resistant Pseudomonas aeruginosa in community hospitals in Japan. J. Clin. Microbiol. 45:979-989.
43. Song, Z., A. Kharazmi, H. Wu, V. Faber, C. Moser, H. K. Krogh, J. Rygaard, and N. Hoiby. 1998. Effects of ginseng treatment on neutrophil chemiluminescence and immunoglobulin G subclasses in a rat model of chronic Pseudomonas aeruginosa pneumonia. Clin. Diagn. Lab. Immunol. 5:882-887.
44. Spiegelberg, H. L. 1989. Biological role of different antibody classes. Int. Arch. Allergy Appl. Immunol. 90(Suppl. 1):22-27.
45. ter Meulen, J. 2007. Monoclonal antibodies for prophylaxis and therapy of infectious diseases. Expert Opin. Emerg. Drugs 12:525-540.
46. Zuercher, A. W., M. P. Horn, J. U. Que, A. Ruedeberg, M. H. Schoeni, U. B. Schaad, P. Marcus, and A. B. Lang. 2006. Antibody responses induced by long-term vaccination with an octovalent conjugate Pseudomonas aeruginosa vaccine in children with cystic fibrosis. FEMS Immunol. Med. Microbiol. 47: 302-308.
47. Zweerink, H. J., M. C. Gammon, C. F. Hutchison, J. J. Jackson, D. Lombardo, K. M. Miner, J. M. Puckett, T. J. Sewell, and N. H. Sigal. 1988. Human monoclonal antibodies that protect mice against challenge with Pseudomonas aeruginosa. Infect. Immun. 56:1873-1879.
48. Zweerink, H. J., M. C. Gammon, C. F. Hutchison, J. J. Jackson, G. B. Pier, J. M. Puckett, T. J. Sewell, and N. H. Sigal. 1988. X-linked immunodeficient mice as a model for testing the protective efficacy of monoclonal antibodies against Pseudomonas aeruginosa. Infect. Immun. 56:1209-1214.